All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2017-04-13T09:08:28.000Z

AACR 2017 | Overexpression of PD-L1 contributes to immune evasion of Adult T-Cell Leukemia/Lymphoma

Apr 13, 2017
Share:

Bookmark this article

On Monday 3rd April at AACR 2017, during the “SY16 - Mechanisms Regulating Immune Checkpoint Therapies” session, Seishi Ogawa of Kyoto University Graduate School of Medicine, Kyoto-shi Sakyo-ku, Japan, gave a talk titled “A novel genetic mechanism of evading antitumor immunity in multiple human cancers.”

The talk began by explaining that tumor cells utilize PD-L1 signaling to escape from the host’s immune response; immunotherapy resulting in PD-L1 blockade prevents this occurring.

Antibodies against PD-1/PD-L1 include nivolumab and pembrolizumab and can be used against a variety of cancer types including lung, kidney, ovarian, colorectal, and head & neck cancers, as well as melanoma and Hodgkin Lymphoma. In those that do respond, anti-PD-1/PD-L1 antibodies achieve durable responses. However, ORR is only around 20–30% and super responders are rare (1–2%). Organ damage (sometimes life-threatening) can occur because of auto-immunity and there are currently no reliable markers for predicting response.

Seishi Ogawa then focused the talk of Adult T-Cell Leukemia/Lymphoma (ATL):

There is a long latency period before the onset of ATL. Infection with HTLV-1 is not enough to develop ATL; genetic alterations in cellular and/or viral genes are required.

During genetic analysis of ATL samples, a novel breakpoint cluster was identified at the PD-L1 locus (9p24.1). This area is affected by a range of Structural Variants (SVs) which often result in the 3’ UTR being disrupted; often truncating the 3’ UTR. In SV+ ATL samples, PD-L1 expression has been found to be increased.

Moreover, surface expression and PD-1 binding ability is preserved in aberrantly expressed PD-L1, and experiments disrupting the 3’ UTR resulted in stabilization of PD-L1 transcripts.

In other cancers, such as Lung Adenocarcinoma and Skin Squamous Cell Cancer, as PD-L1 expression increases, anti-tumor response (cytolytic activity) decreases.

Moreover, Ogawa presented data of a mouse SV+ thymoma model which demonstrated that cancer cells escape the immune response, however administration of αPd-l1 antibody disrupts immune evasion resulting in a decrease in tumor volume. Other slides were also presented, showing data that disruption of PD-L2 3’ UTR also increases PD-L2 expression.

The talk was concluded with a succinct summary slide, and Ogawa emphasized the unexpected role of 3’ UTR regulation in expression of PD-L1 and PD-L2. Screening for SVs involving 3’ UTRs could potentially identify patients whose cancers actively evade their immune response, and could become a novel marker for predicting patients’ responses to therapy using immune checkpoint blockade.

  1. Ogawa S. A novel genetic mechanism of evading antitumor immunity in multiple human cancers [Presentation]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; 2017. Abstract nr [SY09-02].

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox